Skip to main content

Table 3 Frequencies of CDKN2A variant alleles in cases and controls

From: Some Molecular and Clinical Aspects of Genetic Predisposition to Malignant Melanoma and Tumours of Various Site of Origin

Groups A148T OR 95% CI Nt500c>g OR 95% CI Nt540c>t OR 95% CI
newborns 0 (0%) A/A - 6 (1.2%) G/G - 4 (0.8%) T/T -
(n = 500) 14 (2.8%) G/A - 88 (17.6%) G/C - 62 (12.4%) C/T -
  486 (97.2%) G/G - 406 (81.2%) C/C - 434 (86.8%) C/C -
adults 0 (0%) A/A - 9 (1.3%) G/G - 3 (0.4%) T/T -
(n = 710) 21 (2.95%) G/A - 143 (20.1%) G/C - 83 (11.7%) C/T -
  689 (97.05%) G/G - 558 (78.6%) C/C - 625 (88%) C/C -
total controls
(n = 1210)
0 (0%) A/A - 15 (1.2%) G/G - 7 (0.6%) T/T -
  35 (2.89%) G/A - 229 (18.9%) G/C - 145 (12%) C/T -
  1175(97.1%)GG - 966 (79.8%) C/C - 1058(87.4%)C/C -
  Allel A 1.5% - Allel G 10.7% - Allel T 6.6% -
MM* 0 (0%) A/A - 8 (1.7%) G/G 1.44 0.6–3.3 3 (0.6%) T/T 1.14 0.3–4.3
(n = 471) 33 (7%) G/A 2.51 1.5–4.1 103 (21.9%) G/C 1.24 0.9–1.6 64 (13.5%) C/T 1.24 0.8–1.6
  438 (93%) G/G 0.41 0.2–0.6 360 (76.4%) C/C 0.84 0.6–1.1 404 (85.7%) C/C 0.94 0.6–1.2
  Allel A 3.5% 2.51 1.5–4.0 Allel G 12.6% 1.24 0.9–1.5 Allel T 7.4% 1.14 0.9–1.5
melanoma ≤ 50
(n = 172)
0 (0%) A/A - 1 (0.6%) G/G 0.54 0.1–3.6 2 (1.2%) T/T 2.04 0.4–9.8
  16 (9.3%) G/A 3.42 1.9–6.4 32 (18.6%) G/C 1.04 0.6–1.5 21 (12.2%) C/T 1.04 0.6–1.7
  156 (90.7%) G/G 0.32 0.2–0.5 139 (80.8%) C/C 1.14 0.7–1.6 149 (86.6%) C/C 0.94 0.6–1.5
  Allel A 4.7% 3.32 1.8–6.1 Allel G 9.9% 0.94 0.6–1.3 Allel T 7.3% 1.14 0.7–1.7
melanoma > 50
(n = 299)
0 (0%) A/A - 7 (2.3%) G/G 1.94 0.8–4.7 1 (0.3%) T/T 0.64 0.1–4.7
  17 (5.7%) G/A 2.03 1.1–3.7 71 (23.7%) G/C 1.34 1.0–1.8 43 (14.4%) C/T 1.24 0.9–1.8
  282 (94.3%) G/G 0.53 0.3–0.9 221 (73.9%) C/C 0.74 0.5–0.9 255 (85.3%) C/C 0.84 0.6–1.2
  Allel A 2.8% 2.03 1.1–3.6 Allel G 14.2% 1.44 1.0–1.8 Allel T 7.5% 1.24 0.8–1.6
  1. *unselected malignant melanomas;
  2. 1p = 0.0003, 2p = 0.0002, 3p = 0.0315, 4p ≥ 0.05 – not statistically significant